Viking Stock: Oral Study Disappoints, Competitor Gets Bought Out (NASDAQ:VKTX)

Group 1 - Viking Therapeutics is currently conducting phase 3 trials for its incretin VK2735, aimed at weight loss and diabetes treatment, indicating a potential wait for significant developments in the biotech sector [1] - The focus of trading activities is on events such as trial results and NDA/BLA approvals, which are critical for biotech stock movements [1] Group 2 - The article does not provide any specific financial data or performance metrics related to Viking Therapeutics or the broader biotech industry [2][3]